Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nadunolimab by Cantargia for Metastatic Biliary Tract Cancer: Likelihood of Approval
Nadunolimab is under clinical development by Cantargia and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Nadunolimab by Cantargia for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Nadunolimab is under clinical development by Cantargia and currently in Phase III for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Nadunolimab by Cantargia for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Nadunolimab is under clinical development by Cantargia and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Nadunolimab by Cantargia for Metastatic Biliary Tract Cancer: Likelihood of Approval
Nadunolimab is under clinical development by Cantargia and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Nadunolimab by Cantargia for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Nadunolimab is under clinical development by Cantargia and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...